GOLDEN, Colo. — May 19, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in Taiwan.
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate. “We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx™ Immune platform,” said Dr. Wilber Huang, President and CEO, Abnova. “We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome.”
“We are pleased to be collaborating with Abnova on the development of their SARS-CoV-2 mRNA vaccine,” commented Chris Cappello, President and CEO, PharmaJet, “Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings.”
For more information about PharmaJet visit www.staging.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free injection systems as a standard of care in the vaccine delivery market. The PharmaJet Needle-free systems are safe, fast, and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® Needle-free Injection System has CE Mark and WHO PQS certification for intradermal injections.
Abnova’s DNAx™ Immune technology enables the rapid production of highly sensitive and specific antibodies for research, in vitro diagnostics, and therapeutic antibody applications. By leveraging the DNAx™ gene sequence antibody response bioinformatics, Abnova is accelerating the development of mRNA vaccines targeting infectious diseases and cancers.
# # #